|
1
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yau T, Chan P, Ng KK, Chok SH, Cheung TT,
Fan ST and Poon RT: Phase 2 open-label study of single-agent
sorafenib in treating advanced hepatocellular carcinoma in a
hepatitis B-endemic Asian population: Presence of lung metastasis
predicts poor response. Cancer. 115:428–436. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Romero Mendez A and Høyer M: Radiation
therapy for liver metastases. Curr Opin Support Palliat Care.
6:97–102. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gallicchio R, Nardelli A, Mainenti P,
Nappi A, Capacchione D, Simeon V, Sirignano C, Abbruzzi F, Barbato
F, Landriscina M, et al: Therapeutic strategies in HCC: Radiation
modalities. BioMed Res Int. 2016:12953292016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harris AL: Hypoxia: a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barker HE, Paget JT, Khan AA and
Harrington KJ: The tumour microenvironment after radiotherapy:
Mechanisms of resistance and recurrence. Nat Rev Cancer.
15:409–425. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Basu Jothy KS, Bahl A, Subramani V, Sharma
DN, Rath GK and Julka PK: Normal tissue complication probability of
fibrosis in radiotherapy of breast cancer: Accelerated partial
breast irradiation vs conventional external-beam radiotherapy. J
Cancer Res Ther. 4:126–130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jeong SY1, Park SJ, Yoon SM, Jung J, Woo
HN, Yi SL, Song SY, Park HJ, Kim C, Lee JS, et al: Systemic
delivery and preclinical evaluation of Au nanoparticle containing
beta-lapachone for radiosensitization. J Control Release.
139:239–245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jung J, Park SJ, Chung HK, Kang HW, Lee
SW, Seo MH, Park HJ, Song SY, Jeong SY and Choi EK: Polymeric
nanoparticles containing taxanes enhance chemoradiotherapeutic
efficacy in non-small cell lung cancer. Int J Radiat Oncol Biol
Phys. 84:e77–e83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Woo HN, Chung HK, Ju EJ, Jung J, Kang HW,
Lee SW, Seo MH, Lee JS, Lee JS, Park HJ, et al: Preclinical
evaluation of injectable sirolimus formulated with polymeric
nanoparticle for cancer therapy. Int J Nanomed. 7:2197–2208.
2012.
|
|
12
|
Yoshikawa M, Ono N, Yodono H, Ichida T and
Nakamura H: Phase II study of hepatic arterial infusion of a
fine-powder formulation of cisplatin for advanced hepatocellular
carcinoma. Hepatol Res. 38:474–483. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pottier A, Borghi E and Levy L: New use of
metals as nanosized radioenhancers. Anticancer Res. 34:443–453.
2014.PubMed/NCBI
|
|
14
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yao X, Panichpisal K, Kurtzman N and
Nugent K: Cisplatin nephrotoxicity: A review. Am J Med Sci.
334:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pabla N and Dong Z: Cisplatin
nephrotoxicity: Mechanisms and renoprotective strategies. Kidney
Int. 73:994–1007. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Yang H, Gu K, Chen J, Rui M and
Jiang GL: In vitro and in vivo study of a nanoliposomal cisplatin
as a radiosensitizer. Int J Nanomed. 6:437–444. 2011. View Article : Google Scholar
|
|
18
|
Guo S, Wang Y, Miao L, Xu Z, Lin CM, Zhang
Y and Huang L: Lipid-coated Cisplatin nanoparticles induce
neighboring effect and exhibit enhanced anticancer efficacy. ACS
Nano. 7:9896–9904. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamada T, Iwabuki H, Kanno T, Tanaka H,
Kawai T, Fukuda H, Kondo A, Seno M, Tanizawa K and Kuroda S:
Physicochemical and immunological characterization of hepatitis B
virus envelope particles exclusively consisting of the entire L
(pre-S1 + pre-S2 + S) protein. Vaccine. 19:3154–3163. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagaoka T, Fukuda T, Yoshida S, Nishimura
H, Yu D, Kuroda S, Tanizawa K, Kondo A, Ueda M, Yamada H, et al:
Characterization of bio-nanocapsule as a transfer vector targeting
human hepatocyte carcinoma by disulfide linkage modification. J
Control Release. 118:348–356. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Q, Jung J, Somiya M, Iijima M,
Yoshimoto N, Niimi T, Maturana AD, Shin SH, Jeong SY, Choi EK, et
al: Virosomes of hepatitis B virus envelope L proteins containing
doxorubicin: Synergistic enhancement of human liver-specific
antitumor growth activity by radiotherapy. Int J Nanomed.
10:4159–4172. 2015.
|
|
22
|
Allen TM and Cullis PR: Liposomal drug
delivery systems: From concept to clinical applications. Adv Drug
Deliv Rev. 65:36–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Drummond DC, Meyer O, Hong K, Kirpotin DB
and Papahadjopoulos D: Optimizing liposomes for delivery of
chemotherapeutic agents to solid tumors. Pharmacol Rev. 51:691–743.
1999.PubMed/NCBI
|
|
24
|
Deshpande PP, Biswas S and Torchilin VP:
Current trends in the use of liposomes for tumor targeting.
Nanomedicine (Lond). 8:1509–1528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jung J, Iijima M, Yoshimoto N, Sasaki M,
Niimi T, Tatematsu K, Jeong SY, Choi EK, Tanizawa K and Kuroda S:
Efficient and rapid purification of drug- and gene-carrying
bio-nanocapsules, hepatitis B virus surface antigen L particles,
from Saccharomyces cerevisiae. Protein Expr Purif. 78:149–155.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hirai M, Minematsu H, Hiramatsu Y,
Kitagawa H, Otani T, Iwashita S, Kudoh T, Chen L, Li Y, Okada M, et
al: Novel and simple loading procedure of cisplatin into liposomes
and targeting tumor endothelial cells. Int J Pharm. 391:274–283.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dawidczyk CM, Kim C, Park JH, Russell LM,
Lee KH, Pomper MG and Searson PC: State-of-the-art in design rules
for drug delivery platforms: Lessons learned from FDA-approved
nanomedicines. J Control Release. 187:133–144. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jung J, Matsuzaki T, Tatematsu K, Okajima
T, Tanizawa K and Kuroda S: Bio-nanocapsule conjugated with
liposomes for in vivo pinpoint delivery of various materials. J
Control Release. 126:255–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kasuya T, Yamada T, Uyeda A, Matsuzaki T,
Okajima T, Tatematsu K, Tanizawa K and Kuroda S: In vivo protein
delivery to human liver-derived cells using hepatitis B virus
envelope pre-S region. J Biosci Bioeng. 106:99–102. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kasuya T, Jung J, Kinoshita R, Goh Y,
Matsuzaki T, Iijima M, Yoshimoto N, Tanizawa K and Kuroda S:
Chapter 8 - Bio-nanocapsule-liposome conjugates for in vivo
pinpoint drug and gene delivery. Methods Enzymol. 464:147–166.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tatematsu K, Iijima M, Yoshimoto N, Nakai
T, Okajima T and Kuroda S: Bio-nanocapsules displaying various
immunoglobulins as an active targeting-based drug delivery system.
Acta Biomater. 35:238–247. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsutsui Y, Tomizawa K, Nagita M, Michiue
H, Nishiki T, Ohmori I, Seno M, Matsui H, et al: Development of
bionanocapsules targeting brain tumors. J Control Release.
122:159–164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tanguturi SK, Wo JY, Zhu AX, Dawson LA and
Hong TS: Radiation therapy for liver tumors: Ready for inclusion in
guidelines? Oncologist. 19:868–879. 2014. View Article : Google Scholar : PubMed/NCBI
|
